Inhibitors | Comment | Organism | Structure |
---|---|---|---|
antisense oligonucleotide A06007H | +G*+A*+T*T*G*T*C*C*A*G*G*A*+G*+T*+T, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens | |
antisense oligonucleotide A06008H | +C*+T*+C*A*A*C*T*C*T*T*T*C*+T*+C*+G, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens | |
antisense oligonucleotide A06030H | +A*+G*+G*C*G*C*T*G*T*G*A*C*T*+T*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens | |
antisense oligonucleotide A06043H | +C*+C*+A*G*A*C*T*C*T*A*T*G*A*G*+A*+T*+C, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens | |
antisense oligonucleotide A06044H | +G*+A*+G*A*T*G*A*T*C*A*A*T*G*C*+T*+G*+A, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens | |
antisense oligonucleotide A06045H | +A*+G*+G*C*G*C*T*G*T*G*A*C*T*T*+G*+T*+G, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens | |
antisense oligonucleotide A07006H | +T*+G*+T*A*T*G*A*C*A*G*C*+C*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens | |
antisense oligonucleotide A07058H | +A*+T*+C*G*T*G*G*T*G*C*T*G*A*A*+C*+A*+A, (+) LNA-modified nucleotide, (*) PTO linkage | Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-tryptophan + O2 | Homo sapiens | - |
N-formyl-L-kynurenine | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | P14902 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
EFO-21 cell | - |
Homo sapiens | - |
SKOV-3 cell | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
L-tryptophan + O2 | - |
Homo sapiens | N-formyl-L-kynurenine | - |
? |
Synonyms | Comment | Organism |
---|---|---|
IDO1 | - |
Homo sapiens |
indoleamine 2,3-dioxygenase 1 | - |
Homo sapiens |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.000011 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A06030H | |
0.000017 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A06007H | |
0.000036 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A06008H | |
0.000049 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A06043H | |
0.000078 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A06045H | |
0.000205 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A06044H | |
0.000368 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A07006H | |
0.000842 | - |
pH and temperature not specified in the publication, cellular assay of kynurenine production | Homo sapiens | antisense oligonucleotide A07058H |
General Information | Comment | Organism |
---|---|---|
drug target | combined treatment of cancer cells in vitro with indoleamine 2,3-dioxygenase 1-specific antisense oligonucleotides and small molecule inhibitors can reduce the production of kynurenine by cancer cells in a synergistic manner | Homo sapiens |
physiological function | key enzyme in degradation of tryptophan into immunosuppressive kynurenine | Homo sapiens |